Promising Activity Of Nelfinavir-Bortezomib-Dexamethasone In Proteasome Inhibitor-Refractory Multiple Myeloma

Christoph Driessen,Rouven Müller,Urban Novak,Nathan Cantoni,Daniel Betticher,Nicolas Mach,Axel Rüfer,Ulrich Mey,Panagiotis Samaras,Karin Ribi,Lenka Besse,Andrej Besse,Catherine Berset,Stephanie Rondeau,Hanne Hawle,Felicitas Hitz,Thomas Pabst,Thilo Zander

BLOOD（2018）

引用 33|浏览59

暂无评分

摘要

TO THE EDITOR:Treatment of proteasome inhibitor (PI)–refractory multiple myeloma (MM) is challenging, with response rates of only 15% to 35% being achieved with next-generation drugs such as pomalidomide, carfilzomib, and daratumumab, alone or in combination.[1][1][⇓][2]-[3][3]The oral HIV

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要